Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Inks Drug Discovery Deal with Shionogi

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said that it has signed an agreement to use its Evolution platform to conduct drug discovery services for Japanese pharmaceutical firm Shionogi.

The German drug discovery and development firm said that it will identify for Shionogi small molecule modulators of various protein-protein interaction targets. It will use its Evolution platform, which combines biochemical and biophysical techniques including nuclear magnetic resonance, surface plasmon resonance, and X-ray crystallography, as part of the collaboration.

Financial and other terms were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.